ForSight Robotics, an Israel-based surgical robotics company, has secured $125m in a Series B funding round to further develop and commercialise its ophthalmic robotic surgery platform.
The investment round was led by Eclipse, with additional contributions from an unnamed strategic backer, Dr. Fred Moll, Adani Group, Reiya Ventures, and other existing investors. This new round brings the company’s total capital raised to $195m.
The medical technology firm has built the ORYOM Platform, a robotic surgical system specifically designed for cataract and other ophthalmic conditions. The system integrates artificial intelligence (AI), computer vision, and micro-mechanical components to execute precise and consistent procedures within the human eye.
According to ForSight Robotics, the platform is engineered to access both anterior and posterior eye segments, enabling potential expansion into glaucoma and retinal surgeries.
Eclipse partner Seth Winterroth said: “ForSight Robotics is at the forefront of a transformation in surgical robotics, and the potential impact of its technology on global eye care is extraordinary.
“The company is tapping into a massive, underserved market with a breakthrough approach to ophthalmic surgery, positioning itself to set a new standard in eye care and drive innovation on a global scale.”
The latest funding will be used to support the initiation of first-in-human clinical trials later this year. These trials are part of the company’s strategic objective to offer increased access to ophthalmic care while also reducing the physical strain associated with traditional surgical practices.
ForSight Robotics said that ORYOM will aim to deliver greater surgical accuracy, expand treatment access, and improve surgeon ergonomics.
ForSight Robotics co-founder, president, and chief medical officer Joseph Nathan said: “We see ophthalmology as the next frontier in the robotics revolution – much like general surgery was before the rise of Intuitive Surgical. With a comparable market size and an urgent global need, our opportunity ahead is immense.
“Through our latest funding round, we will bring the same level of transformative impact to eye surgery, with technology designed specifically for its unique precision and complexity.”
In February 2025, ForSight Robotics also announced its attainment of the ISO 13485:2016 certification, which sets out requirements for quality management systems in the medical device sector. The certification supports the company’s compliance with international standards for the design, development, and manufacture of robotic systems and microscopes used in ophthalmic procedures.
This regulatory milestone forms part of the company’s broader plan to meet evolving global medical device standards and ensure safety and performance as the technology scales. The company stated that the certification reinforces its approach to continuous improvement and regulatory alignment as it progresses toward commercial deployment.
ForSight Robotics secures new investment to expand ophthalmic surgery platform.
